Incidence-Based Breast Cancer Mortality Trends in Estonia Before and After the Introduction of Organized Mammography Screening: A Register-Based Study.

IF 2.5 4区 医学 Q3 ONCOLOGY
Aleksei Baburin, Piret Veerus, Katrin Lang, Kaire Innos
{"title":"Incidence-Based Breast Cancer Mortality Trends in Estonia Before and After the Introduction of Organized Mammography Screening: A Register-Based Study.","authors":"Aleksei Baburin, Piret Veerus, Katrin Lang, Kaire Innos","doi":"10.1177/10732748241266491","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite the relatively low breast cancer incidence in Estonia, mortality remains high, and participation in mammography screening is below the recommended 70%. The objective of this register-based study was to evaluate incidence-based (IB) breast cancer mortality before and after the introduction of organized mammography screening in 2004.</p><p><strong>Methods: </strong>Breast cancer deaths individually linked to breast cancer diagnosis were obtained from the Estonian Cancer Registry and used for calculating IB mortality. We compared age-specific IB mortality rates across 5-year birth cohorts and 5-year periods. Poisson regression was used to compare IB mortality for one age group invited to screening (50-63) and three age groups not invited to screening (30-49, 65-69, and 70+) during two periods before and after screening initiation (1993-2003 and 2004-2014). Joinpoint regression was used for age-standardized incidence and IB mortality trends.</p><p><strong>Results: </strong>Age-standardized IB mortality has been decreasing since 1997. Age-specific IB mortality for birth cohorts never exposed to screening showed a continuous increase with age, while in cohorts exposed to organized screening the mortality curve flattened or declined after the age of first invitation. Significant decreases in mortality from 1993-2003 to 2004-2014 were seen in the 30-49 (age-adjusted rate ratio 0.51, 95% CI 90.42-0.63) and 50-63 (0.65, 95% CI 0.56-0.74) age groups, while no decline was seen in the 65-69 and 70+ age groups.</p><p><strong>Conclusions: </strong>The age specific IB mortality curves in birth cohorts exposed to screening and the significant mortality decline in the target age group after the initiation of the organized program suggest a beneficial effect of screening. Improved treatment without screening has not reduced mortality in older age groups. Our results support raising the upper screening age limit to 74 years.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"31 ","pages":"10732748241266491"},"PeriodicalIF":2.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11297520/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Control","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10732748241266491","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Despite the relatively low breast cancer incidence in Estonia, mortality remains high, and participation in mammography screening is below the recommended 70%. The objective of this register-based study was to evaluate incidence-based (IB) breast cancer mortality before and after the introduction of organized mammography screening in 2004.

Methods: Breast cancer deaths individually linked to breast cancer diagnosis were obtained from the Estonian Cancer Registry and used for calculating IB mortality. We compared age-specific IB mortality rates across 5-year birth cohorts and 5-year periods. Poisson regression was used to compare IB mortality for one age group invited to screening (50-63) and three age groups not invited to screening (30-49, 65-69, and 70+) during two periods before and after screening initiation (1993-2003 and 2004-2014). Joinpoint regression was used for age-standardized incidence and IB mortality trends.

Results: Age-standardized IB mortality has been decreasing since 1997. Age-specific IB mortality for birth cohorts never exposed to screening showed a continuous increase with age, while in cohorts exposed to organized screening the mortality curve flattened or declined after the age of first invitation. Significant decreases in mortality from 1993-2003 to 2004-2014 were seen in the 30-49 (age-adjusted rate ratio 0.51, 95% CI 90.42-0.63) and 50-63 (0.65, 95% CI 0.56-0.74) age groups, while no decline was seen in the 65-69 and 70+ age groups.

Conclusions: The age specific IB mortality curves in birth cohorts exposed to screening and the significant mortality decline in the target age group after the initiation of the organized program suggest a beneficial effect of screening. Improved treatment without screening has not reduced mortality in older age groups. Our results support raising the upper screening age limit to 74 years.

爱沙尼亚在引入有组织的乳房 X 射线照相筛查前后基于发病率的乳腺癌死亡率趋势:一项基于登记册的研究。
背景:尽管爱沙尼亚的乳腺癌发病率相对较低,但死亡率仍然很高,乳房 X 射线照相筛查的参与率低于建议的 70%。这项以登记为基础的研究旨在评估 2004 年引入有组织的乳房 X 光筛查前后基于发病率(IB)的乳腺癌死亡率:从爱沙尼亚癌症登记处获得了与乳腺癌诊断相关的乳腺癌死亡病例,并用于计算 IB 死亡率。我们比较了 5 年出生队列和 5 年期间的特定年龄 IB 死亡率。在筛查开始前后的两个时期(1993-2003 年和 2004-2014 年),我们使用泊松回归法比较了受邀参加筛查的一个年龄组(50-63 岁)和未受邀参加筛查的三个年龄组(30-49 岁、65-69 岁和 70 岁以上)的 IB 死亡率。对年龄标准化的发病率和 IB 死亡率趋势采用了连接点回归法:结果:自 1997 年以来,年龄标准化的 IB 死亡率一直在下降。在从未接受筛查的出生队列中,特定年龄的 IB 死亡率随年龄的增长而持续上升,而在接受有组织筛查的队列中,死亡率曲线在首次邀请年龄之后趋于平缓或下降。从1993-2003年到2004-2014年,30-49岁(年龄调整比率为0.51,95% CI为90.42-0.63)和50-63岁(0.65,95% CI为0.56-0.74)年龄组的死亡率显著下降,而65-69岁和70岁以上年龄组的死亡率没有下降:接受筛查的出生队列中特定年龄组的 IB 死亡率曲线,以及有组织计划启动后目标年龄组死亡率的显著下降,都表明筛查产生了有益的影响。在没有筛查的情况下改进治疗并没有降低高龄人群的死亡率。我们的研究结果支持将筛查年龄上限提高到 74 岁。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Control
Cancer Control ONCOLOGY-
CiteScore
3.80
自引率
0.00%
发文量
148
审稿时长
>12 weeks
期刊介绍: Cancer Control is a JCR-ranked, peer-reviewed open access journal whose mission is to advance the prevention, detection, diagnosis, treatment, and palliative care of cancer by enabling researchers, doctors, policymakers, and other healthcare professionals to freely share research along the cancer control continuum. Our vision is a world where gold-standard cancer care is the norm, not the exception.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信